Recurv Pharma
Wilmington
About Recurv Pharma
Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $24.0M
- Last round: Series Unknown (Feb 2023)
Industries & Categories
Life Science, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/recurv-pharma-157492 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.